WO2024157195 - TREATING CANCER WITH AN ADENOSINE A 2A INHIBITOR
National phase entry is expected:
Publication Number
WO/2024/157195
Publication Date
02.08.2024
International Application No.
PCT/IB2024/050682
International Filing Date
25.01.2024
Title **
[English]
TREATING CANCER WITH AN ADENOSINE A 2A INHIBITOR
[French]
TRAITEMENT DU CANCER AVEC UN INHIBITEUR DE L'ADÉNOSINE A 2A
Applicants **
IMPETIS BIOSCIENCES LIMITED
Inventors
MOOKHTIAR, Kasim A.
DE, Siddhartha
MERU, Ashwinkumar V.
Priority Data
63/441,090
25.01.2023
US
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
EPO
* |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| Translation |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 2527 | |
| EPO | Filing, Examination, Granting | 15585 | |
| Japan | Filing, Examination, Granting | 2600 | |
| South Korea | Filing, Examination, Granting | 3033 | |
| USA | Filing, Examination, Granting | 6140 |
Total:
29,885
The term for entry into the National Phase has expired. This quotation is for informational purposes only
Contact Us
Abstract[English]
Methods for treating cancers, including solid tumors, by administering the compound PNQ-370 (5-amino-3-[2-[ 4-[2-fluoro-4-(2-methoxyethoxy)phenyl]piperazin-1-yl]ethyl]-8-(2-furyl)-1-methyl- [1,2,4] triazolo[5,1-f]purin-2-one) to selectively antagonize the A2A receptor are described. The methods comprise orally administering PNQ-370 to a subject in need at particular doses. In an embodiment, the method comprises administering a second compound that has activity to inhibit/antagonize (i) an adenosine A2B receptor and/or (ii) a checkpoint programmed death 1 (PD-1) receptor.[French]
L'invention concerne des méthodes de traitement de cancers, comprenant des tumeurs solides, par administration du composé PNQ-370 (5-amino-3-[2-[4-[2-fluoro-4-(2-méthoxyéthoxy)phényl]pipérazin-1-yl]éthyl]-8-(2-furyl)-1-méthyl-[1,2,4]triazolo[5,1-f]purin-2-one) pour antagoniser sélectivement le récepteur A2A. Les méthodes comprennent l'administration orale de PNQ-370 à un sujet en ayant besoin à des doses particulières. Dans un mode de réalisation, la méthode comprend l'administration d'un second composé qui a une activité pour inhiber/antagoniser (i) un récepteur d'adénosine A2B et/ou (ii) un récepteur de mort programmée 1 (PD-1) de point de contrôle.